Transgene SA (TNG) NPV

Sell:€0.71Buy:€0.72€0.00 (0.28%)

Prices delayed by at least 15 minutes
Sell:€0.71
Buy:€0.72
Change:€0.00 (0.28%)
Deal now
Prices delayed by at least 15 minutes
Sell:€0.71
Buy:€0.72
Change:€0.00 (0.28%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Key people

Alessandro Riva
Chairman of the Board, Chief Executive Officer, Member of the Management Committee
Lucie Larguier
Chief Financial Officer, Member of the Management Committee
Christelle Schwoerer
Chief Human Resource Officer, Member of the Management Committee
Maurizio Ceppi
Chief Scientific Officer, Member of the Management Committee
John Felitti
General Counsel, Corporate Secretary, Member of the Management Committee
Christophe Ancel
Chief Pharmaceutical Operations Officer & Qualified Pharmacist, Member of the Management Committee
Emmanuelle Dochy
Chief Medical Officer, Member of the Management Committee
James Wentworth
Chief Business Officer, Member of the Management Committee
Sandrine Flory
Director - Representative of TSGH
Philippe Archinard
Non-Executive Director
Jean-Luc Belingard
Non-Executive Director
Michel Baguenault de Puchesse
Non-Executive Director
Benoit Habert
Non-Executive Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    FR0005175080
  • Market cap
    €94.85m
  • Employees
    162
  • Shares in issue
    101.40m
  • Exchange
    Euronext Paris
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.